How has been the historical performance of Prism Medico?

Answer:The historical performance of Prism Medico shows significant growth in net sales over the years, increasing from 5.28 Cr in March 2017 to 54.73 Cr in March 2019. The total operating income followed a similar trend, rising from 5.28 Cr in March 2017 to 54.73 Cr in March 2019. However, the company faced challenges with profitability, as indicated by the profit before tax, which was negative at -0.10 Cr in March 2019, after being positive at 0.07 Cr in March 2018. The profit after tax also fluctuated, showing a small profit of 0.04 Cr in March 2019, compared to a loss of -0.00 Cr in March 2018 and -0.22 Cr in March 2017. In terms of expenses, total expenditure increased from 5.22 Cr in March 2017 to 54.33 Cr in March 2019, with a notable rise in the purchase of finished goods. The operating profit margin decreased from 3.33% in March 2018 to 0.73% in March 2019, reflecting the rising costs relative to sales. The company's total assets grew from 17.26 Cr in March 2017 to 21.13 Cr in March 2019, while total liabilities also increased from 17.26 Cr to 21.13 Cr in the same period. Cash flow remained stagnant, with no cash inflow or outflow reported in the cash flow results for the years presented. Breakdown: Prism Medico's financial trajectory from March 2016 to March 2019 reveals a robust increase in net sales, which surged from 0.00 Cr in March 2016 to 54.73 Cr in March 2019, indicating a strong market presence. Despite this growth in revenue, the company struggled with profitability, experiencing a profit before tax of -0.10 Cr in March 2019, down from a profit of 0.07 Cr in March 2018. The profit after tax showed a slight recovery to 0.04 Cr in March 2019, following losses in the previous years. Total expenditure rose significantly, reflecting increased operational costs, particularly in the purchase of finished goods, which reached 53.13 Cr in March 2019. The operating profit margin declined to 0.73% in March 2019, suggesting that rising costs are outpacing revenue growth. The balance sheet indicates total assets increased to 21.13 Cr, alongside a rise in total liabilities, which also reached 21.13 Cr, highlighting a growing leverage position. Cash flow remained unchanged, with no reported inflows or outflows, indicating potential liquidity challenges.